Share on LinkedInShare on LinkedIn

ARTICLE · 12 AUGUST 2015

Practical Implications From Amarin

Amarin is an important US district court opinion affirming the importance of the Second Circuit's Caronia decision.

United StatesFood, Drugs, Healthcare, Life Sciences
Lisa Dykstra
Lisa Dykstra
Kathleen Sanzo
Kathleen Sanzo
Alison Tanchyk
Alison Tanchyk
John Rah
John Rah
Brianna Abrams
Brianna Abrams

Amarin is an important US district court opinion affirming the importance of the Second Circuit's Caronia decision and finding that pharmaceutical and medical device companies have a constitutionally protected right to provide truthful and non-misleading information regarding off-label uses of their products.

The US District Court for the Southern District of New York ruled against the Food and Drug Administration (FDA) and upheld the rights of a pharmaceutical manufacturer to make truthful and non-misleading statements regarding off-label uses of its FDA-approved drug, including the right to affirmatively make those statements through sales representatives to healthcare providers, following the US Court of Appeals for the Second Circuit's landmark opinion in United States v. Caronia.1

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from